Revenue: $502 million in Q1 2025, up 37% from $368 million in Q1 2024. Gross Margin: 63% in Q1 2025, with an improvement of over 110 basis points from Q4 2024. Cash Flow: Generated $23 million in cash during Q1 2025. Revenue Guidance: Raised to $1.94 billion to $2.02 billion for 2025, a $70 million increase from prior guidance. Signatera Clinical Volumes: Grew 52% year-on-year, with a sequential increase of 16,500 units from Q4 2024. Units Processed: 855,000 units in Q1 2025, an 8% sequential increase from Q4 2024. Women's Health Volumes: Grew more than 40,000 units sequentially in Q1 2025. Organ Health Growth: Over 50% year-on-year growth in Q1 2025. Signatera ASP: Moved above $1,100 in Q1 2025. Balance Sheet: Nearly $1 billion in cash with no debt outside of a line of credit.

Warning! GuruFocus has detected 4 Warning Signs with NTRA.

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Natera Inc (NASDAQ:NTRA) reported a 37% year-over-year revenue growth, reaching $502 million in Q1 2025. The company processed 855,000 units in the quarter, marking a significant increase in women's health volumes and a record quarter for Signatera. Gross margins improved to 63%, with a notable increase of over 110 basis points compared to Q4 2024. Natera Inc (NASDAQ:NTRA) raised its revenue guidance for 2025 to a range of $1.94 billion to $2.02 billion, reflecting strong growth expectations. The company generated $23 million in cash during the quarter, even while investing heavily in growth initiatives.

Negative Points

Natera Inc (NASDAQ:NTRA) faces potential risks from weather disruptions, as seen with the wildfires in Southern California affecting operations. The company acknowledges challenges in achieving reimbursement for certain tests, impacting average selling prices (ASPs). There is uncertainty regarding the timing of new guidelines for microdeletions and carrier screening, which could impact future revenue. Despite strong growth, the company is still in the early stages of market penetration, with significant room for expansion. Natera Inc (NASDAQ:NTRA) faces competition in the MRD testing market, which could impact its market share and growth trajectory.

Q & A Highlights

Q: Can you explain the factors driving the strong sequential volume growth in Signatera, and is this growth sustainable throughout the year? A: Steven Chapman, CEO: We're pleased with the record sequential growth, driven by the strong clinical utility of our test and our large commercial presence. The data we've generated is resonating with physicians, and our focus on user experience, such as quick turnaround times and EMR capabilities, is contributing to this growth. While we're not changing our previous growth estimates, we're optimistic about continued utilization and excitement moving forward.

Story Continues

Q: With the upcoming clinical evidence at ESMO and ASCO, which studies should we focus on that could significantly impact market volumes? A: Steven Chapman, CEO: We're excited about more than 25 presentations at ASCO, including 6 oral presentations. Key studies include the I-SPY 2 trial and the DARE study, which are generating significant interest. These studies, started years ago, continue to solidify our leadership in the space. Solomon Moshkevich, President - Clinical Diagnostics, added that the INVIGR-011 trial with Genentech could significantly impact GU with muscle-invasive bladder cancer.

Q: Is there a difference in the number of tests reimbursed for breast versus CRC in the recurrent setting, and are there studies to define optimal testing frequency for breast cancer? A: Steven Chapman, CEO: Reimbursement processes consider standard imaging cadences, which vary by tumor site. While there are differences in testing frequency, we see opportunities to improve reimbursement for tests performed between reimbursed time points. We believe Signatera ASPs can increase over time as we secure coverage for more tests.

Q: Did weather or calendar dynamics impact Q1 results, and how do you view revenue seasonality in Q2? A: Michael Brophy, CFO: Weather, particularly wildfires in Southern California, was a challenge, but we managed to maintain strong volumes. These tests are time-sensitive, and patients typically return quickly for testing. For Q2, we expect standard seasonality in women's health, with volumes dropping in Q2 and recovering in Q3 and Q4. Signatera and Prospera continue to ramp without marked seasonality.

Q: Can you provide an update on the progress and potential impact of the Signatera launch in Japan? A: Solomon Moshkevich, President - Clinical Diagnostics: We're on track with our program in Japan, having submitted to the PMDA. We expect approval by late this year or early next year, followed by a submission for reimbursement, which could impact our top line by late next year. There's significant demand for MRD-guided treatment decisions in Japan, with MRD already mentioned in society guidelines.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments